lifestyle.timesla.com

Author: Jaguar Health, Inc.

Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company Updates

April 29, 2026
Jaguar Health Completes Effectiveness Trial to Support FDA Approved Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

April 29, 2026
Jaguar Health Reports 2025 Financials

April 28, 2026
Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress

April 28, 2026
FDA Feedback Supports Extension Phase for Jaguar Health’s Clinical Trial of Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)

March 18, 2026
Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts

March 11, 2026
Jaguar Health Strengthens Company’s Balance Sheet by Restructuring and Reducing Royalty and Debt Obligations and Extinguishing Warrants

March 9, 2026
Jaguar Health Secures an Additional $3 Million Payment from Future Pak for Mytesi and Canalevia-CA1

March 3, 2026
Reminder: Today, March 2, 2026, is the Record Date for Jaguar Health’s Special One-time Stock Dividend

March 2, 2026
Jaguar Health Announces a Special One-time Stock Dividend

February 18, 2026